

Applicants: David M. Stern et al.
U.S. Serial No.: 09/394,204
Filed: September 10, 1999
Page 2

Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application:

1-19. (Canceled)

20. (Currently Amended) A method for ~~evaluating the ability of~~
determining whether an agent ~~to inhibit~~ inhibits binding of
human ERAB polypeptide (SEQ. ID. NO: 2), or a fragment ~~or~~
~~polymorphism~~ thereof, to amyloid-beta peptide which comprises:

(a) incubating human ERAB polypeptide (SEQ. ID. NO: 2), or
a fragment ~~or polymorphism~~ thereof, the agent and
amyloid-beta peptide under suitable binding
conditions;

(b) determining the amount of amyloid-beta peptide bound
to the polypeptide, or fragment ~~or polymorphism~~ from
the incubate of (a); and

(c) comparing the amount of bound amyloid-beta peptide
~~determined in step (b)~~ to an amount of amyloid-beta
peptide bound to the polypeptide, or fragment ~~or~~
~~polymorphism~~ determined in the absence of the agent,
wherein when the amount of amyloid-beta polypeptide
bound to the polypeptide, or fragment ~~or polymorphism~~
thereof is decreased in the presence of said agent,
the ~~ability of the agent to inhibit~~ inhibits binding
of human ERAB polypeptide (SEQ. ID. NO: 2), or the

Applicants: David M. Stern et al.
U.S. Serial No.: 09/394,204
Filed: September 10, 1999
Page 3

fragment ~~or polymorphism~~ thereof, ~~to amyloid beta is~~
determined.

21-26. (Canceled)

27. (Previously Presented) The method of claim 20, wherein the agent is a peptide.
28. (Previously Presented) The method of claim 20, wherein the agent is a peptidomimetic compound.
29. (Previously Presented) The method of claim 20, wherein the agent is a nucleic acid.
30. (Previously Presented) The method of claim 20, wherein the agent is a small molecule.